Search academic texts

Information × Registration Number 0214U005003, 0111U001126 , R & D reports Title To develop the methods of prognosis of development, medical treatment and prevention of cardiovascular complications at patients with essential hypertension with metabolic syndrome and uric acide metabolism disorders. popup.stage_title Head S. Koval, Registration Date 28-01-2014 Organization Government institution "L.T. Malaya Therapy Institute National Academy of Medical Sciences of Ukraine" popup.description2 The object of study - patients with essential hypertension (EH) 2-3 degree with metabolic syndrome (MS) and hyperuricemia (HUE) and without MS and HUE. Research methods - clinical, biochemical, ELISA, tool. According to a study by means of multivariate regression analysis and the creation of binary logistic regression models were developed ways to predict the development of hypertension in patients with MS and with/without HUE those cardiovascular lesions, as left ventricular concentric hypertrophy, microalbuminuria and stable exertional angina. The most important prognostic cardio-metabolic risk factors for each of these cardiovascular lesions were established. An effective approach to the treatment of hypertensive patients with metabolic syndrome in combination with or without HUE, which are able to inhibit the development of complications in these patients. The effective in terms of antihypertensive and with optimal clinical and pathogenetic perspective for the treatment of hypertensive patients with MS and with or without HUE antihypertensive therapy is a combination of RAS blockers (ACE inhibitors or angiotensin II antagonists) or highly selective beta adrenoblocker with vasodilatative effects nebivolol in combination with long-acting calcium antagonist (lercanidipine) were shown. In hypertensive patients with metabolic syndrome and HUE or normouricemie the presence of coronary artery disease and atherogenic DLP and in case of elevated levels of CRP and VEGF in order to prevent progression of cardiovascular lesions appropriate use of RAS blockers (ACE inhibitors or angiotensin II antagonists) in combination with statins, including atorvastatin were shown. In hypertensive patients with metabolic syndrome and HUE, especially at the level of anymore or equal 400 mmol/l, only the addition of allopurinol led to a significant reduction of uric acid levels with no adverse effects on lipid and carbohydrate metabolism. Therefore this patient expedient short-term (within 4-8 weeks) use of allopurinol in low daily doses (50-100 mg). Product Description popup.authors Божко В.В. Висоцька О.В. Гудков С.М. Зоренко Н.В. Корнійчук І.А. Лавренко Т.А. Мазій В.В. Милославський Д.К. Мисниченко О.В. Остапюк О.С. Пенькова М.Ю. Самохіна Л.М. Снігурська І.О. Страшненко Г.М. Щенявська О.М. Ярина Н.А. popup.nrat_date 2020-04-02 Close